[Click eStock] "Genians Strengthens Growth Momentum with Vaccine Launch"

Growth Research analyzed on September 11 that Genians has strengthened its growth momentum with the launch of its vaccine product.

Han Yonghee, a researcher at Growth Research, stated, "Genians launched its vaccine (AV) solution as a strategic choice to expand its customer base," adding, "This was developed in response to requests from around 200 EDR client companies for integrated use of both vaccine and EDR."

He continued, "From the customer's perspective, installing multiple agents can lead to performance degradation and complicated management," and added, "They prefer a method where both EDR and the vaccine can be managed in a single agent."

He further anticipated, "Since there are not many functional differences among recent vaccine solutions, customers already using EDR are likely to naturally prefer integration into a single agent."

Researcher Han analyzed, "There should not be significant difficulties in expanding the vaccine client base," but added, "After launch, the vaccine solution will require a period for securing stability and technical verification." He also noted, "Technical verification is currently underway at large enterprises," and predicted, "Once verification is complete, it will start contributing to revenue in earnest from next year."

This content was produced with the assistance of AI translation services.